## Comprehensive Report: Legend Biotech Corporation (LEGN)

### Company Profile
**Industry:** Biotechnology  
**Sector:** Healthcare  
**Address:** 2101 Cottontail Lane, Somerset, NJ, 08873, United States  
**Phone:** 732 317 5050  
**Website:** [Legend Biotech](https://www.legendbiotech.com)  
**Employees:** 2000  
**Business Summary:**  
Legend Biotech Corporation is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cell therapies for oncology and other indications. Its leading product candidate is LCAR-B38M, a CAR-T therapy for multiple myeloma. The company has a broad portfolio targeting various cancers and a collaboration with Janssen Biotech for ciltacabtagene autoleucel.

### Current Performance
- **Current Price:** $53.99
- **52-Week Range:** $38.60 - $77.32
- **Volume:** 2,366,338
- **Market Cap:** $9.841 billion

### Financials
- **Total Revenue (2023):** $285.143 million
- **EBITDA (2023):** -$425.375 million
- **Net Income (2023):** -$518.254 million
- **Total Cash:** $1.302 billion
- **Total Debt:** $334.686 million
- **Cash Per Share:** $3.572
- **Debt to Equity:** 28.752%
- **Current Ratio:** 5.663

### Valuation Ratios
- **Price to Sales (TTM):** 28.71
- **Forward P/E:** -99.98 (reflective of expected losses)

### Analyst Ratings
- **Recommendation Mean:** 1.8 (Buy)
- **Number of Analyst Opinions:** 21
- **Target Price Range:** $60.00 - $95.00
- **Median Target Price:** $86.00

### Technical Indicators
- **20-Day Moving Average:** $45.478
- **50-Day Moving Average:** $44.532
- **100-Day Moving Average:** $50.880
- **200-Day Moving Average:** $56.305

### Risk Factors
- Legend Biotech operates in a highly competitive and regulated industry.
- The company is still in a clinical-stage, with significant ongoing expenses and no guarantee of product success or profitability.
- Fluctuations in research funding and changes in health regulations can impact performance.

### Swing Trading Potential
The current technical setup shows a potential for short-term trading opportunities. The price has recently moved above its 20-day and 50-day moving averages, suggesting a bullish trend. However, traders should be cautious due to the high volatility and the company's fundamental challenges.

### Risk Assessment (Scale 1-10, where 10 is most risky): 7
Given the clinical-stage nature of the company, ongoing cash burn, and the speculative nature of biotech investments, the risk is relatively high.

### Trade Status
trade_status: Don't Trade

This recommendation takes into account the high-risk nature of the investment relative to a risk tolerance of 7, suggesting that it may not be suitable for those with moderate risk tolerance despite the possible upside depicted by analysts and recent bullish technical indicators.